Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition

Huang, Guoyu; Cai, Guohao; Hu, Dongwei; Li, Jinjie; Xu, Qi; Chen, Zongjing; Xu, Bo

doi:10.1007/s13402-022-00722-4

Cited by 5 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SUMO1 protein was found to inhibit the SUMOylation level of SP1, which led to upregulated lncRNA SNHG17 expression in the SNHG17 promoter. The high level of lncRNA SNHG17 can bind to miR-23b-3p as a sponge, leading to decreased inhibition of the target gene Notch2 , which finally promotes the resistance of GC to DDP [ 144 ]. As a member of RNA-binding proteins, transcription factors were also closely related to the regulation of lncRNA expression.…”

Section: Mechanisms Of Drug Resistance-related Lncrnas In Gcmentioning

confidence: 99%

“…Regarding the role of drug resistance in gastric cancer, we also found that other signaling pathways are involved, such as the Notch signaling pathway and the p53 signaling pathway, by reviewing the documents selected for this review. In terms of the Notch signaling pathway, SNHG17 can positively regulate Notch2 protein expression through the ceRNA mechanism and then activate the Notch signaling pathway to induce drug resistance in gastric cancer [ 144 ]. Some lncRNAs that negatively regulate signaling pathways have also been found to regulate drug resistance mechanisms in gastric cancer.…”

Section: Mechanisms Of Drug Resistance-related Lncrnas In Gcmentioning

confidence: 99%

“…protein expression through the ceRNA mechanism and then activate the Notch signaling pathway to induce drug resistance in gastric cancer [144]. Some lncRNAs that negatively regulate signaling pathways have also been found to regulate drug resistance mechanisms in gastric cancer.…”

Section: Drug Resistance-related Lncrna-mediated Regulation Of Cell S...mentioning

confidence: 99%

See 2 more Smart Citations

Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications

Meng,

Bai,

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Gastric cancer (GC) ranks as the third most prevalent malignancy and a leading cause of cancer-related mortality worldwide. However, the majority of patients with GC are diagnosed at an advanced stage, highlighting the urgent need for effective perioperative and postoperative chemotherapy to prevent relapse and metastasis. The current treatment strategies have limited overall efficacy because of intrinsic or acquired drug resistance. Recent evidence suggests that dysregulated long non-coding RNAs (lncRNAs) play a significant role in mediating drug resistance in GC. Therefore, there is an imperative to explore novel molecular mechanisms underlying drug resistance in order to overcome this challenging issue. With advancements in deep transcriptome sequencing technology, lncRNAs—once considered transcriptional noise—have garnered widespread attention as potential regulators of carcinogenesis, including tumor cell proliferation, metastasis, and sensitivity to chemo- or radiotherapy through multiple regulatory mechanisms. In light of these findings, we aim to review the mechanisms by which lncRNAs contribute to drug therapy resistance in GC with the goal of providing new insights and breakthroughs toward overcoming this formidable obstacle.

show abstract

Section: Mechanisms Of Drug Resistance-related Lncrnas In Gcmentioning

confidence: 99%

Section: Mechanisms Of Drug Resistance-related Lncrnas In Gcmentioning

confidence: 99%

See 1 more Smart Citation

Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications

Meng,

Bai,

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Therefore, SUMOi is expected to restore antigen presentation machinery and augment the killing effect of CD8(+) T cells in the TME [ 180 ]. Moreover, a low SUMOylation level of SP1 contributes to SP1 and SNHG17 upregulation, which results in drug resistance through activating the Notch2 pathway in GC [ 181 ]. Although not mentioned by the authors, recent studies have shown the crucial role of the Notch2 pathway in TME remodeling in terms of regulating the anti-tumor infiltrate, which is likely to cause resistance [ 182 ].…”

Section: Multiple Functions Of Sumoylation In Cancersmentioning

confidence: 99%

The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications

Fang

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Tumor initiation, progression, and response to therapies depend to a great extent on interactions between malignant cells and the tumor microenvironment (TME), which denotes the cancerous/non-cancerous cells, cytokines, chemokines, and various other factors around tumors. Cancer cells as well as stroma cells can not only obtain adaption to the TME but also sculpt their microenvironment through a series of signaling pathways. The post-translational modification (PTM) of eukaryotic cells by small ubiquitin-related modifier (SUMO) proteins is now recognized as a key flexible pathway. Proteins involved in tumorigenesis guiding several biological processes including chromatin organization, DNA repair, transcription, protein trafficking, and signal conduction rely on SUMOylation. The purpose of this review is to explore the role that SUMOylation plays in the TME formation and reprogramming, emphasize the importance of targeting SUMOylation to intervene in the TME and discuss the potential of SUMOylation inhibitors (SUMOi) in ameliorating tumor prognosis.

show abstract

Role of non-canonical post-translational modifications in gastrointestinal tumors

Liu,

Peng

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

Post-translational modifications (PTMs) of proteins contribute to the occurrence and development of tumors. Previous studies have suggested that canonical PTMs such as ubiquitination, glycosylation, and phosphorylation are closely implicated in different aspects of gastrointestinal tumors. Recently, emerging evidence showed that non-canonical PTMs play an essential role in the carcinogenesis, metastasis and treatment of gastrointestinal tumors. Therefore, we summarized recent advances in sumoylation, neddylation, isoprenylation, succinylation and other non-canonical PTMs in gastrointestinal tumors, which comprehensively describe the mechanisms and functions of non-classical PTMs in gastrointestinal tumors. It is anticipated that targeting specific PTMs could benefit the treatment as well as improve the prognosis of gastrointestinal tumors.

show abstract

Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition

Cited by 5 publications

References 43 publications

Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications

Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications

The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications

Role of non-canonical post-translational modifications in gastrointestinal tumors

Contact Info

Product

Resources

About